B
씨엔알리서치
359090KOSDAQ56.5 / 100
Reference Date: 2026-10-23
Financial Score20.0 / 40
News Sentiment12.5 / 25
Momentum14.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Rose 7.3% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
CNR Research, established in 1997 as Korea's first CRO, provides clinical trial services for drug development, including Phase I-III trials for regulatory approval and post-market studies (PMS/Phase IV). It maintains the top position among domestic CROs by revenue in 2023 and aims to expand globally through IT solution development and oncology trial expertise.
Number of Employees
522people
Average Salary
58.3M KRW
Score Calculation Basis
Detailed Financial Score
PER
50.33Industry Average 15.000.0Point
3.4x industry avg (risky)
PBR
0.54Industry Average 1.207.0Point
Half of industry avg (excellent)
ROE
2.15Industry Average 8.001.0Point
Well below industry avg
Debt Ratio
5.27Industry Average 100.008.0Point
Half of industry avg (excellent)
Trend 2023~20254.0 / 10 points
Revenue Growth Rate
2.0 / 3
Avg ▲8.6% (2-year basis)
Operating Profit Growth Rate
0.0 / 3
Avg ▼51.8% (2-year basis)
ROE Trend
2.0 / 4
Avg ROE 7.9% (declining, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position8.0Point
Near 52w high (94%, uptrend)
Current 2,265Won52-week high 2,37552-week low 511
1-month return5.0Point
1m +7.35% (rising)
Volume trend1.0Point
Volume decreasing
Detailed Disclosure
0 totalPositive 0Neutral 0Negative 0